PMID: 41881032 MedComm (2020) Caffeic acid, but not ferulic acid, inhibits macrophage pyroptosis by directly blocking gasdermin D activation
Retatrutide is a groundbreaking triple agonist currently in Phase 3 trials that is redefining what is possible without surgery: Triple-Action Mechanism: Unlike Wegovy (1 receptor) or Zepbound (2 receptors), Retatrutide targets three hormones: GLP-1, GIP, and Glucagon
Receptor downregulation: Continuous high exposure could desensitize receptors
Antidepressants and high blood pressure medications are commonly used for preventive treatment, as are some new injectables like Aimovig
Editors Highlight: Metformin Protects Against Acetaminophen Hepatotoxicity by Attenuation of Mitochondrial Oxidant Stress and Dysfunction
As the battery gets closer to empty, the voltage falls faster